The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
Open accessAbstract
Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h of awakening is believed to augment low hypothalamic dopamine levels and inhibit excessive sympathetic tone within the central nervous system (CNS), resulting in a reduction in postmeal plasma glucose levels due to enhanced suppression of hepatic glucose production. Bromocriptine has not been shown to augment insulin secretion or enhance insulin sensitivity in peripheral tissues (muscle). Addition of bromocriptine to poorly controlled type 2 diabetic patients treated with diet alone, metformin, sulfonylureas, or thiazolidinediones produces a 0.5–0.7 decrement in HbA1c. Bromocriptine also reduces fasting and postmeal plasma free fatty acid (FFA) and triglyceride levels. In a 52 double-blind, placebo-controlled study in type 2 diabetic patients, bromocriptine reduced the composite cardiovascular end point by 40%. The mechanism of the drug’s beneficial effect on cardiovascular disease remains to be determined. ### Introduction Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance, impaired β-cell function, and multiple other metabolic/endocrine abnormalities (1). Because of its multifactorial pathogenesis, restoration of normoglycemia is difficult to achieve and requires multiple antidiabetic medications that have different mechanisms of action and can be used in combination to produce an additive effect (1,2). Therefore, the development of antidiabetic agents that have novel mechanisms of action and can be used in combination with currently approved medications for the treatment of type 2 diabetes is highly desirable. Type 2 diabetic patients are at high risk for atherosclerotic cardiovascular complications (3). Although hyperglycemia is a risk factor for coronary artery disease and stroke, it is a relatively weak risk factor compared with other more established risk factors such as dyslipidemia, hypertension, obesity, and the insulin resistance (metabolic) syndrome (4, …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535
Self-citationDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationDiabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"?
(1962) · PubMed Central · Cited by 2,182
Wang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864
Authors/Task Force Members, Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,647
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Self-citation(1975) · Springer eBooks · doi:10.1007/978-3-642-66033-7 · Cited by 456
Luiten, P. G. M., ter Horst, G. J., & Steffens, A. B. (1987) · Progress in Neurobiology · doi:10.1016/0301-0082(87)90004-9 · Cited by 390
Borg, M. A., Sherwin, R. S., Borg, W. P., Tamborlane, W. V., & Shulman, G. I. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119165 · Cited by 359
Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases: Executive Summary
Rydén, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., De Boer, M.-J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(07)60205-9 · Cited by 242
Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl, H., Ohashi, S., Matsuda, M., Miyazaki, Y., Mahankali, A., Kumar, V, Pipek, R., Iozzo, P., Lancaster, J. L., Cincotta, A. H., et al. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1154 · Cited by 238
Self-citationGaziano, J. M., Cincotta, A. H., O'Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z. J., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 213
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 194
The insulin resistance syndrome
Reaven, G. M. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0007-0 · Cited by 188
Neuronal regulation of hepatic glucose metabolism in mammals
Shimazu, T. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030109 · Cited by 185
Koch‐Weser, J., & Parkes, D. (1979) · New England Journal of Medicine · doi:10.1056/nejm197910183011606 · Cited by 144
Cincotta, A. H., MEIER, A. H., & Cincotta, M. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1683 · Cited by 140
Bromocriptine (Ergoset) Reduces Body Weight and Improves Glucose Tolerance in Obese Subjects
Cincotta, A. H., & MEIER, A. H. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.667 · Cited by 135
Rao, G. (2012) · Springer eBooks · doi:10.1007/978-3-540-29807-6_4297 · Cited by 128
Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet-induced obese rats
Levin, B. E., & Dunn-Meynell, A. A. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.272.5.r1365 · Cited by 127
Pijl, H. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.100 · Cited by 107
Kamath, V., Jones, C. N. O., Yip, J. C., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.11.1697 · Cited by 103
Luo, S., MEIER, A. H., & Cincotta, A. H. (1998) · Neuroendocrinology · doi:10.1159/000054344 · Cited by 102
Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes
Scranton, R. E., & Cincotta, A. H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903501544 · Cited by 96
Luo, S., Liang, Y. T., & Cincotta, A. H. (1999) · Neuroendocrinology · doi:10.1159/000054415 · Cited by 89
Ścisłowski, P. W. D., Tozzo, E., Zhang, Y., Phaneuf, S., Prevelige, R., & Cincotta, A. H. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800893 · Cited by 84
Cincotta, A. H., & MEIER, A. H. (1995) · Metabolism · doi:10.1016/0026-0495(95)90041-1 · Cited by 71
Jones, A. P., Pothos, E. N., Rada, P. V., Olster, D. H., & Hoebel, B. G. (1995) · Developmental Brain Research · doi:10.1016/0165-3806(95)00078-r · Cited by 70
Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob)
Oltmans, G. (1983) · Brain Research · doi:10.1016/0006-8993(83)90865-x · Cited by 64
Luo, S., Luo, J., & Cincotta, A. H. (1999) · Neuroendocrinology · doi:10.1159/000054508 · Cited by 63
Dopamine and serotonin VMN release is related to feeding status in obese and lean Zucker rats
Meguid, M. M., Fetissov, S. O., Blaha, V., & Yang, Z.-J. (2000) · Neuroreport · doi:10.1097/00001756-200007140-00002 · Cited by 62
Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy
Wijnhoven, T. J. M., van den Hoven, M. J. W., Ding, H. G., Kuppevelt, T. H. V., van der Vlag, J., Berden, J. H. M., Prinz, R. A., Lewis, E. J., Schwartz, M. M., & Xu, X. (2007) · Diabetologia · doi:10.1007/s00125-007-0879-6 · Cited by 61
Luo, S., Luo, J., MEIER, A. H., & Cincotta, A. H. (1997) · Neuroreport · doi:10.1097/00001756-199711100-00016 · Cited by 47
Cincotta, A. H., Luo, S., Zhang, Y., Liang, Y. T., Bina, K. G., Jetton, T. L., & Ścisłowski, P. W. D. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.2.r435 · Cited by 41
Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters
Luo, S., Luo, J., & Cincotta, A. H. (1999) · Neuroreport · doi:10.1097/00001756-199907130-00015 · Cited by 35
Centrally Mediated Effects of Bromocriptine on Cardiac Sympathovagal Balance
Franchi, F., Lazzeri, C., Barletta, G., Ianni, L., & Mannelli, M. (2001) · Hypertension · doi:10.1161/01.hyp.38.1.123 · Cited by 29
Hypothalamic adrenergic receptor changes in the metabolic syndrome of genetically obese (ob/ob) mice
Boundy, V. A., & Cincotta, A. H. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.2.r505 · Cited by 21
Liang, Y. T., & Cincotta, A. H. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801614 · Cited by 19
Inhibitory effects of bromocriptine on vascular smooth muscle cell proliferation
Zhang, Y., & Cincotta, A. H. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00113-5 · Cited by 18
(1962) · Europe PMC (PubMed Central)
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
Self-citation
Metadata
- Authors
- DeFronzo, R. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 789-794
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2107582181
- Cited by
- 257
- References
- 42
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.